Showing results (11-20 of 29) with videos related to
Sort By:
Pageof 3
Current Opinion in Infectious Diseases|January 29, 2020
Fungal infections of the skin and soft tissueSibel Dogan Gunaydin, Sevtap Arikan-Akdagli, Murat AkovaIndian Journal of Dermatology|August 7, 2018
Lipedematous Scalp and Alopecia: Report of Two Cases with a Brief Review of LiteratureEfsun Kilinc, Sibel Dogan, Hande Akinci, et al.Skinmed|March 18, 2011
High frequency of psoriasis in relatives in a Turkish multiple sclerosis cohortSibel Dogan, Nilgün Atakan, Asli Kurne, et al.Dermatologic Therapy|May 16, 2019
Long-term effects of omalizumab on peripheral blood cells and C-reactive protein levels in patients with chronic spontaneous urticariaNeslihan Akdogan, Neslihan Demirel Ogut, Sibel Dogan, et al.International Journal of Clinical Practice|October 5, 2021
Comparison of rituximab and intravenous immunoglobulin in the treatment of autoimmune bullous diseases: Real-life data from a single centreLeyla Huseynova Terzi, Neslihan Akdogan, Sibel Dogan Gunaydin, et al.Expert Review of Clinical Pharmacology|July 12, 2024
Psoriatic arthritis, biologic therapy experience, body mass index, and onset age of psoriasis were independent factors of secukinumab discontinuation in patients with psoriasisNeslihan Akdogan, Kerem Balan, Basak Yalici Armagan, et al.Skinmed|July 15, 2017
Childhood-Onset Keratosis Lichenoides Chronica Accompanied by Severe Hair LossSibel Dogan, Efsun Kılınç, Gül Erkin Özaygen, et al.Archives of Dermatological Research|November 16, 2019
Serum amyloid A and C-reactive protein levels and erythrocyte sedimentation rate are important indicators in hidradenitis suppurativaNeslihan Akdogan, Sibel Dogan, Pinar Incel-Uysal, et al.Journal of Cosmetic Dermatology|August 8, 2021
Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease courseBasak Yalici-Armagan, Gulsun Hazan Tabak, Sibel Dogan-Gunaydin, et al.Expert Review of Clinical Pharmacology|June 27, 2025
Early response is a strong predictor of the long-term response in psoriasis patients receiving risankizumab or guselkumab in the real-world: a retrospective analysisNeslihan Akdogan, Ömer Kutay Mutlu, Erdem Karabulut, et al.Pageof 3